Difference between revisions of "Polycythemia vera"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 11: Line 11:
  
 
=Relapsed, refractory, or intolerant=
 
=Relapsed, refractory, or intolerant=
 +
 +
==Anagrelide (Agrylin) {{#subobject:7c6a2d|Regimen=1}}==
 +
 +
===Regimen {{#subobject:50dda2|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 +
|-
 +
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1409002 Vannucchi et al. 2015 (RESPONSE)]
 +
|<span
 +
style="background:#00CD00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III</span>
 +
|[[Polycythemia_vera#Ruxolitinib_.28Jakafi.29|Ruxolitinib]]
 +
|<span
 +
style="background:#ff0000;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Decreased disease control</span>
 +
|-
 +
|}
 +
To be completed
 +
 +
===References===
 +
# Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. [http://www.nejm.org/doi/full/10.1056/NEJMoa1409002 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25629741 PubMed]
 +
 +
==Hydroxyurea (Hydrea) {{#subobject:82ab4d|Regimen=1}}==
 +
 +
===Regimen {{#subobject:14ace8|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 +
|-
 +
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1409002 Vannucchi et al. 2015 (RESPONSE)]
 +
|<span
 +
style="background:#00CD00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III</span>
 +
|[[Polycythemia_vera#Ruxolitinib_.28Jakafi.29|Ruxolitinib]]
 +
|<span
 +
style="background:#ff0000;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Decreased disease control</span>
 +
|-
 +
|}
 +
To be completed
 +
 +
===References===
 +
# Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. [http://www.nejm.org/doi/full/10.1056/NEJMoa1409002 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25629741 PubMed]
  
 
==Ruxolitinib (Jakafi) {{#subobject:f35a21|Regimen=1}}==
 
==Ruxolitinib (Jakafi) {{#subobject:f35a21|Regimen=1}}==
Line 18: Line 78:
 
|}
 
|}
  
−
===Regimen, Verstovsek et al. 2014 {{#subobject:364cac|Variant=1}}===
+
===Regimen {{#subobject:364cac|Variant=1}}===
−
<span  
+
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 +
|-
 +
|[http://onlinelibrary.wiley.com/doi/10.1002/cncr.28441/full Verstovsek et al. 2014]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 25: Line 92:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
−
 
+
|N/A
−
''There were several doses evaluated in this cohort; the median total daily dose was 21.7 mg corresponding to approximately 10 mg PO twice per day.''
+
|N/A
 +
|-
 +
!colspan="4" align="center"|
 +
|-
 +
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1409002 Vannucchi et al. 2015 (RESPONSE)]
 +
|<span
 +
style="background:#00CD00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III</span>
 +
|Standard therapy
 +
|<span
 +
style="background:#00CD00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Increased disease control</span>
 +
|-
 +
|}
 +
''There were several doses evaluated in Verstovsek et al. 2014; the median total daily dose was 21.7 mg corresponding to approximately 10 mg PO twice per day. The most common comparator in RESPONSE was hydroxyurea, followed by interferon and anagrelide.''
  
 
*[[Ruxolitinib (Jakafi)]] 10 mg PO twice per day
 
*[[Ruxolitinib (Jakafi)]] 10 mg PO twice per day
Line 34: Line 121:
 
===References===
 
===References===
 
# Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513-20. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.28441/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24258498 PubMed] content property of [http://hemonc.org HemOnc.org]
 
# Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513-20. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.28441/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24258498 PubMed] content property of [http://hemonc.org HemOnc.org]
 +
# Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. [http://www.nejm.org/doi/full/10.1056/NEJMoa1409002 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25629741 PubMed]

Revision as of 01:34, 21 February 2015

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

10 regimens on this page
11 variants on this page


Relapsed, refractory, or intolerant

Anagrelide (Agrylin)

Regimen

Study Evidence Comparator Efficacy
Vannucchi et al. 2015 (RESPONSE) Phase III Ruxolitinib Decreased disease control

To be completed

References

  1. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. link to original article contains verified protocol PubMed

Hydroxyurea (Hydrea)

Regimen

Study Evidence Comparator Efficacy
Vannucchi et al. 2015 (RESPONSE) Phase III Ruxolitinib Decreased disease control

To be completed

References

  1. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. link to original article contains verified protocol PubMed

Ruxolitinib (Jakafi)

back to top

Regimen

Study Evidence Comparator Efficacy
Verstovsek et al. 2014 Phase II N/A N/A
Vannucchi et al. 2015 (RESPONSE) Phase III Standard therapy Increased disease control

There were several doses evaluated in Verstovsek et al. 2014; the median total daily dose was 21.7 mg corresponding to approximately 10 mg PO twice per day. The most common comparator in RESPONSE was hydroxyurea, followed by interferon and anagrelide.

Continued until progression or excess toxicity

References

  1. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513-20. link to original article contains verified protocol PubMed content property of HemOnc.org
  2. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Polycythemia_vera&oldid=7258"